Huntington's Disease: Can Mice Lead the Way to Treatment?
暂无分享,去创建一个
[1] J. Mysore,et al. Factors associated with HD CAG repeat instability in Huntington disease , 2007, Journal of Medical Genetics.
[2] K. Murphy,et al. Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease , 2007, Brain Research Bulletin.
[3] S. Frank. Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study , 2011, BMC Neurology.
[4] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[5] A. J. Morton,et al. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease , 2009, Neurobiology of Disease.
[6] M. Chesselet,et al. Mouse models of Huntington's disease. , 2002, Trends in pharmacological sciences.
[7] Dimitri Krainc,et al. Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.
[8] G. Bernardi,et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene , 2001, The European journal of neuroscience.
[9] He Li,et al. Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease , 2003, The Journal of Neuroscience.
[10] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[11] M. Hayden,et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Tsuji,et al. CAG repeat disorder models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.
[13] Patrik Brundin,et al. The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies , 2005, NeuroRX.
[14] J. Schiefer,et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[15] P. Brundin,et al. Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease , 2002, Experimental Neurology.
[16] Steven M Hersch,et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice , 2005, The Journal of comparative neurology.
[17] D. Wilkin,et al. Neuron , 2001, Brain Research.
[18] M. Hayden,et al. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.
[19] Peter S. Harper,et al. Huntington's disease , 1991 .
[20] A. Messer,et al. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice , 1999, Nature Genetics.
[21] Yun-Ping Deng,et al. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice , 2002, The Journal of comparative neurology.
[22] W. Low,et al. Age‐Dependent Changes in the Calcium Sensitivity of Striatal Mitochondria in Mouse Models of Huntington's Disease , 2005, Journal of neurochemistry.
[23] Ole A. Andreassen,et al. Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.
[24] Michelle K. Lupton,et al. The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes , 2007, Brain Research Bulletin.
[25] Y. Kawaoka,et al. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.
[26] D. Borchelt,et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.
[27] He Li,et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity , 2000, Nature Genetics.
[28] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[29] M. Chesselet,et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice , 2008, Neuroscience.
[30] M. Chesselet,et al. Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice , 2002, The Journal of Neuroscience.
[31] Danielle A. Simmons,et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice , 2009, Proceedings of the National Academy of Sciences.
[32] D. Borchelt,et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice , 2004, Experimental Neurology.
[33] S. Dunnett,et al. Rule learning, visuospatial function and motor performance in the HdhQ92 knock-in mouse model of Huntington's disease , 2009, Behavioural Brain Research.
[34] Yu Deng,et al. Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease , 2009, The Journal of Neuroscience.
[35] J. M. Boutell,et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.
[36] J. Jankovic,et al. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. , 2008, Archives of neurology.
[37] A. Reiner,et al. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice , 2007, The Journal of comparative neurology.
[38] J. Palo,et al. [Huntington's disease]. , 1986, Duodecim; laaketieteellinen aikakauskirja.
[39] A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease , 2001, Neurology.
[40] S. Snider,et al. Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.
[41] M. Hayden,et al. Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.
[42] D. Brooks,et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.
[43] J. Olson,et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. , 2002, Human molecular genetics.
[44] S. W. Davies,et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[45] Xi Chen,et al. Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.
[46] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[47] Jacki Y. Brown,et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. , 2006, Human molecular genetics.
[48] Howard Schulman,et al. Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.
[49] A. Morton,et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice , 2009, Neurobiology of Disease.
[50] K. Fenger,et al. Molecular and behavioral analysis of the r6/1 huntington′s disease transgenic mouse , 2003, Neuroscience.
[51] K. Murphy,et al. Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset , 2007, Brain Research Bulletin.
[52] M. Dragunow,et al. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.
[53] D. Housman,et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Myers,et al. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. , 1999, Human molecular genetics.
[55] C. Blakemore,et al. Dendritic spine pathology and deficits in experience‐dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice , 2004, The European journal of neuroscience.
[56] C A Ross,et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.
[57] O. Andreassen,et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. , 2001, Neurobiology of disease.
[58] I. Módy,et al. Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.
[59] Chuan-en Wang,et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.
[60] D. Sengelaub,et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse , 2008, Neuroscience.
[61] Cristina Sampaio,et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. , 2009, The Cochrane database of systematic reviews.
[62] Colin Blakemore,et al. Delaying the onset of Huntington's in mice , 2000, Nature.
[63] J. Schiefer,et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.
[64] Michael I. Miller,et al. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images , 2010, NeuroImage.
[65] Blair R. Leavitt,et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease , 2005, Experimental Neurology.
[66] Roger L Albin,et al. Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[67] J. Olson,et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. , 2002, Human molecular genetics.
[68] M. Mcdermott,et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.
[69] S. Hersch,et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.
[70] S. Finkbeiner,et al. Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice , 2009, Neuron.
[71] C. Tanner,et al. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. , 1990, Movement disorders : official journal of the Movement Disorder Society.
[72] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[73] L. Raymond,et al. Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.
[74] M. Beal,et al. Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease* , 2005, Journal of Biological Chemistry.
[75] A. Young,et al. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. , 2005, Human molecular genetics.
[76] J. Olson,et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration , 2007, The Journal of Neuroscience.
[77] A. Morton,et al. Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.
[78] E. Hirsch,et al. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset , 1998, Neuroreport.
[79] O. Andreassen,et al. Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.
[80] Carlos Cepeda,et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.
[81] Bruce R. Rosen,et al. Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.
[82] M. MacDonald,et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models , 2009, Neurobiology of Disease.
[83] R. Mott,et al. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation , 1997, Nature Genetics.
[84] R. Albin,et al. Neuronal intranuclear inclusions and neuropil aggregates in Hdh CAG(150) knockin mice , 2005, Neuroscience.
[85] F. Pierelli,et al. The gender effect in juvenile Huntington disease patients of Italian origin , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[86] L. Ellerby,et al. Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice , 2007, Journal of neurochemistry.
[87] Ruth Luthi-Carter,et al. Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.
[88] S B Dunnett,et al. Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.
[89] K. Fenger,et al. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. , 1993, Human molecular genetics.
[90] A. Rego,et al. The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease , 2009, Brain Research Reviews.
[91] S. Frank. Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators , 2009, BMC neurology.
[92] C A Ross,et al. Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.
[93] Huntington's disease transgenic mice are resistant to global cerebral ischemia , 2002, Neuroscience Letters.
[94] R. Yasuda,et al. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.
[95] C. Blakemore,et al. Impaired learning-dependent cortical plasticity in Huntington's disease transgenic mice , 2004, Neurobiology of Disease.
[96] M. Mehler,et al. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease , 2009, Proceedings of the National Academy of Sciences.
[97] C. Ross,et al. Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.
[98] G. Rebec,et al. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease , 2007, Behavioural Brain Research.
[99] I. Kanazawa,et al. Age‐dependent and tissue‐specific CAG repeat instability occurs in mouse knock‐in for a mutant Huntington's disease gene , 2001, Journal of neuroscience research.
[100] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[101] Stephen B. Dunnett,et al. Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.
[102] Dosage effects of riluzole in Huntington’s disease , 2003, Neurology.
[103] M. MacDonald,et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.
[104] Jacqueline K. White,et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. , 1999, Human molecular genetics.
[105] P. Klivényi,et al. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[106] P. Patterson,et al. Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease , 2009, The Journal of Neuroscience.
[107] Leslie M Thompson,et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[108] Minocycline safety and tolerability in Huntington disease , 2004, Neurology.
[109] Mauro Delorenzi,et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.
[110] S. Tavaré,et al. Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism. , 1999, Human molecular genetics.
[111] S. Hersch,et al. Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice , 2007, The Journal of Neuroscience.
[112] X. Chen,et al. Tetrabenazine is neuroprotective in Huntington's disease mice , 2010, Molecular Neurodegeneration.
[113] P. Shelbourne,et al. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? , 2000, Human molecular genetics.
[114] M. MacDonald,et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. , 2002, Human molecular genetics.
[115] J. Gusella,et al. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease , 1993, Nature genetics.
[116] Aman A. Savani,et al. Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.
[117] 仙波 宏史,et al. 症例報告 抗N-methyl-D-aspartate receptor脳炎を発症した成熟囊胞性奇形腫の1例 , 2013 .
[118] I. Martins,et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[119] Giovanni Coppola,et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice , 2008, Proceedings of the National Academy of Sciences.
[120] Ole A. Andreassen,et al. Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.
[121] M. Hayden,et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.
[122] A. Morton,et al. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation , 2000, Journal of neurocytology.
[123] R. Mechoulam,et al. Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors , 2007, The European journal of neuroscience.
[124] Dimitri Krainc,et al. Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.
[125] R. Albin,et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.
[126] I. Módy,et al. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease , 2008, Neuroscience.
[127] P. Djian,et al. Protein aggregation in Huntington's disease. , 2002, Biochimie.
[128] M. MacDonald,et al. Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.
[129] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[130] Elizabeth Evans,et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. , 2003, Human molecular genetics.
[131] O. Andreassen,et al. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease , 2005, Journal of neurochemistry.
[132] J. Lucas,et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain , 2006, The European journal of neuroscience.
[133] J. Coyle,et al. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. , 1976, Nature.
[134] M. Mcdermott,et al. A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[135] G. Bates,et al. Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease , 2009, PloS one.
[136] S. Augood,et al. Huntingtin inclusions do not down‐regulate specific genes in the R6/2 Huntington's disease mouse , 2006, The European journal of neuroscience.
[137] O. Hansson,et al. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[138] M. Chesselet,et al. Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.
[139] Scott J Barton,et al. Altered Information Processing in the Prefrontal Cortex of Huntington's Disease Mouse Models , 2008, The Journal of Neuroscience.
[140] M. Chesselet,et al. Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.
[141] J. Coyle,et al. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.
[142] Nicola Pavese,et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.
[143] M. MacDonald,et al. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. , 2003, Human molecular genetics.
[144] C. Blakemore,et al. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine , 2005, The European journal of neuroscience.
[145] P. Holmans,et al. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington’s disease , 2008, Genes, brain, and behavior.
[146] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[147] E. Simpson,et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.
[148] P. Klivényi,et al. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease , 2009, Pharmacology Biochemistry and Behavior.
[149] Carlos Cepeda,et al. Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.
[150] D. Burns,et al. Neuroanatomic Profile of Polyglutamine Immunoreactivity inHuntington Disease Brains , 2009, Journal of neuropathology and experimental neurology.
[151] H. Johnston,et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. , 1999, Human molecular genetics.
[152] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[153] M. F. Beal,et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.
[154] M. Chesselet,et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.
[155] O. Isacson,et al. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. , 2008, Human molecular genetics.